Shanghai Kaibao (300039.SZ) stated on the investor interaction platform on June 12th that the Tantieqing series includes Tantieqing injection and Tantieqing capsules. The main effect of the Tantieqing injection is to clear heat, detoxify, and resolve phlegm. It is mainly used for the treatment of acute and chronic bronchitis, pneumonia, and upper respiratory tract infections caused by bacteria or viruses. The Tantieqing injection has been listed as a clinical guideline or treatment plan drug by the National Health Commission and the State Administration of Traditional Chinese Medicine in the prevention and control of avian influenza, influenza A (H1N1), influenza A (H7N9), hand, foot and mouth disease, dengue fever, Ebola, Middle East respiratory syndrome, and COVID-19. In 2006, the Tantieqing injection was listed by the National Development and Reform Commission as a reserve drug for influenza prevention and treatment in Chinese patent medicine and became a national strategic reserve drug. The company's Tantieqing injection is mainly developed for the market of secondary and above hospitals.